T-cell antigen-positive multiple myeloma.

Catherine S Perry, T. M. Grogan, B. G. Durie, L. C. Richter, E. Vela, Y. Frutiger, C. S. Rangel

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We report the simultaneous expression of T-cell antigens on the myeloma cells from six patients with multiple myeloma (MM). These six patients come from a total population of 215 samples (115 direct samples, clinical incidence of 5.2%) of plasmacytic malignancies immunotyped at the University of Arizona. Four patients expressed T helper antigen (Leu 3, CD4), one expressed T-cell antigen receptor (Leu 4, CD3), and one expressed E-rosette antigen receptor (Leu 5, CD2). The presenting clinical features, histology, and plasma cell morphology showed no differences from multiple myeloma patients who did not express T-cell antigen. However, although the survival duration ranged from 5 to 93 mo overall, survival from demonstration of T antigen expression was very short, (2 to 7+ mo), with five of six (80%) patients dying less than or equal to 5 mo after study. The reason for T antigen expression is unknown. It may indicate that myeloma can arise from a normally minor subpopulation of B cells involved with immunoregulation; conversely, it could be a coincidental aberrancy associated with malignant change in the plasma cells.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalModern Pathology
Volume3
Issue number3
StatePublished - May 1990

Fingerprint

Viral Tumor Antigens
Multiple Myeloma
T-Lymphocytes
Plasma Cells
Antigen Receptors
Survival
T-Cell Antigen Receptor
Histology
B-Lymphocytes
Incidence
Population
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Perry, C. S., Grogan, T. M., Durie, B. G., Richter, L. C., Vela, E., Frutiger, Y., & Rangel, C. S. (1990). T-cell antigen-positive multiple myeloma. Modern Pathology, 3(3), 302-307.

T-cell antigen-positive multiple myeloma. / Perry, Catherine S; Grogan, T. M.; Durie, B. G.; Richter, L. C.; Vela, E.; Frutiger, Y.; Rangel, C. S.

In: Modern Pathology, Vol. 3, No. 3, 05.1990, p. 302-307.

Research output: Contribution to journalArticle

Perry, CS, Grogan, TM, Durie, BG, Richter, LC, Vela, E, Frutiger, Y & Rangel, CS 1990, 'T-cell antigen-positive multiple myeloma.', Modern Pathology, vol. 3, no. 3, pp. 302-307.
Perry CS, Grogan TM, Durie BG, Richter LC, Vela E, Frutiger Y et al. T-cell antigen-positive multiple myeloma. Modern Pathology. 1990 May;3(3):302-307.
Perry, Catherine S ; Grogan, T. M. ; Durie, B. G. ; Richter, L. C. ; Vela, E. ; Frutiger, Y. ; Rangel, C. S. / T-cell antigen-positive multiple myeloma. In: Modern Pathology. 1990 ; Vol. 3, No. 3. pp. 302-307.
@article{d601c2035c30409185fcc4b2cb746c20,
title = "T-cell antigen-positive multiple myeloma.",
abstract = "We report the simultaneous expression of T-cell antigens on the myeloma cells from six patients with multiple myeloma (MM). These six patients come from a total population of 215 samples (115 direct samples, clinical incidence of 5.2{\%}) of plasmacytic malignancies immunotyped at the University of Arizona. Four patients expressed T helper antigen (Leu 3, CD4), one expressed T-cell antigen receptor (Leu 4, CD3), and one expressed E-rosette antigen receptor (Leu 5, CD2). The presenting clinical features, histology, and plasma cell morphology showed no differences from multiple myeloma patients who did not express T-cell antigen. However, although the survival duration ranged from 5 to 93 mo overall, survival from demonstration of T antigen expression was very short, (2 to 7+ mo), with five of six (80{\%}) patients dying less than or equal to 5 mo after study. The reason for T antigen expression is unknown. It may indicate that myeloma can arise from a normally minor subpopulation of B cells involved with immunoregulation; conversely, it could be a coincidental aberrancy associated with malignant change in the plasma cells.",
author = "Perry, {Catherine S} and Grogan, {T. M.} and Durie, {B. G.} and Richter, {L. C.} and E. Vela and Y. Frutiger and Rangel, {C. S.}",
year = "1990",
month = "5",
language = "English (US)",
volume = "3",
pages = "302--307",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - T-cell antigen-positive multiple myeloma.

AU - Perry, Catherine S

AU - Grogan, T. M.

AU - Durie, B. G.

AU - Richter, L. C.

AU - Vela, E.

AU - Frutiger, Y.

AU - Rangel, C. S.

PY - 1990/5

Y1 - 1990/5

N2 - We report the simultaneous expression of T-cell antigens on the myeloma cells from six patients with multiple myeloma (MM). These six patients come from a total population of 215 samples (115 direct samples, clinical incidence of 5.2%) of plasmacytic malignancies immunotyped at the University of Arizona. Four patients expressed T helper antigen (Leu 3, CD4), one expressed T-cell antigen receptor (Leu 4, CD3), and one expressed E-rosette antigen receptor (Leu 5, CD2). The presenting clinical features, histology, and plasma cell morphology showed no differences from multiple myeloma patients who did not express T-cell antigen. However, although the survival duration ranged from 5 to 93 mo overall, survival from demonstration of T antigen expression was very short, (2 to 7+ mo), with five of six (80%) patients dying less than or equal to 5 mo after study. The reason for T antigen expression is unknown. It may indicate that myeloma can arise from a normally minor subpopulation of B cells involved with immunoregulation; conversely, it could be a coincidental aberrancy associated with malignant change in the plasma cells.

AB - We report the simultaneous expression of T-cell antigens on the myeloma cells from six patients with multiple myeloma (MM). These six patients come from a total population of 215 samples (115 direct samples, clinical incidence of 5.2%) of plasmacytic malignancies immunotyped at the University of Arizona. Four patients expressed T helper antigen (Leu 3, CD4), one expressed T-cell antigen receptor (Leu 4, CD3), and one expressed E-rosette antigen receptor (Leu 5, CD2). The presenting clinical features, histology, and plasma cell morphology showed no differences from multiple myeloma patients who did not express T-cell antigen. However, although the survival duration ranged from 5 to 93 mo overall, survival from demonstration of T antigen expression was very short, (2 to 7+ mo), with five of six (80%) patients dying less than or equal to 5 mo after study. The reason for T antigen expression is unknown. It may indicate that myeloma can arise from a normally minor subpopulation of B cells involved with immunoregulation; conversely, it could be a coincidental aberrancy associated with malignant change in the plasma cells.

UR - http://www.scopus.com/inward/record.url?scp=0025428549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025428549&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 302

EP - 307

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -